

Informa PLC **Press Release**

1 June 2022

Completion of £1.9bn Pharma Intelligence agreement

Portfolio re-balancing and accelerating shareholder returns

Informa (LSE: INF.L), the international Academic Markets, B2B Markets and Digital Services Group today confirmed the completion of its £1.9bn Pharma Intelligence agreement which forms part of the 2021-2024 Growth Acceleration Plan II ("GAP II").

The agreement announced on 10 February sees the Group receive c.£1.7bn in cash before tax deductions and a c.15% shareholding in the ongoing business. This c.15% equity interest ranks pari passu with **Warburg Pincus'** equity (the acquirer), enabling Informa to realise significant value today, whilst sharing in the future value created from further growth and portfolio expansion.

Re-balancing the Group's portfolio is a key part of Informa's *GAP II* programme, a four-year plan designed to create a more focused, higher growth business, with digital and data excellence at its core. Following **Pharma Intelligence**, the Group is now reviewing its **Financial Intelligence** portfolio.

The Group will provide an update on **GAP II Shareholder Returns** within its AGM Trading Update on 16 June 2022. Since March, the Group has completed c.£257m of its current £300m share buyback commitment, at a weighted average price of 581p, leading to the cancellation of c.44m shares.

Enquiries

Stephen A. Carter , Chief Executive	+44 (0) 20 8052 0400
Gareth Wright , Finance Director	+44 (0) 20 8052 0400
Richard Menzies-Gow , Director of IR & Communications	+44 (0) 20 8052 2787
Tim Burt / Simon Duke – Teneo	+44 (0) 20 7240 2486